Keywords: Sanofi-Aventis, Insulin, Research, Rimonabant, Weight loss
Sanofi-Aventis launches major insulin research program; updates on rimonabant court case
Article | 30 September 2009
French drug major Sanofi-Aventis has announced an action plan to provide methodologically robust research that will contribute to the scientific ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
